 Equillium, Inc. EQ, a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that Krishna R. Polu, M.D., chief medical officer, will participate in a panel discussing New Innovations in Drug Therapy as part of the Kidney Capital Markets Day hosted by the American Society of Nephrology ASN and RenalytixAI on Tuesday, November 19, 2019 in London, England. We applaud the ASN for spearheading efforts to gather senior officials from leading health agencies, investors and medical technology and life sciences companies to increase visibility in innovation and investments in all aspects of kidney diseases, said Dr. Polu. 